FMR LLC

FMR LLC has an estimated net worth of $1.53 Billion. This is based on reported shares across multiple companies, which include Fidelity Private Credit Fund, GENERAC HOLDINGS INC., TETRAPHASE PHARMACEUTICALS INC, GT Advanced Technologies Inc., REGENXBIO Inc., Caribou Biosciences, Inc., Aclaris Therapeutics, Inc., ViewRay, Inc., Toast, Inc., Blueprint Medicines Corp, Verve Therapeutics, Inc., Unum Therapeutics Inc., Mersana Therapeutics, Inc., Coherus BioSciences, Inc., Rallybio Corp, Ultragenyx Pharmaceutical Inc., Denali Therapeutics Inc., IRONWOOD PHARMACEUTICALS INC, Flywire Corp, Beam Therapeutics Inc., INSMED Inc, Menlo Therapeutics Inc., Surface Oncology, Inc., Xilio Therapeutics, Inc., Dimension Therapeutics, Inc., PRECISION BIOSCIENCES INC, PROTEOSTASIS THERAPEUTICS, INC., Orchard Therapeutics plc, Structure Therapeutics Inc., EXA CORP, Prime Medicine, Inc., Tropicana Las Vegas Hotel & Casino, Inc., XOOM Corp, ASIAINFO-LINKAGE, INC, ARCHIPELAGO HOLDINGS INC, Neumora Therapeutics, Inc., Turnstone Biologics Corp., Fidelity Multi-Strategy Credit Fund, Sana Biotechnology, Inc., Bicara Therapeutics Inc., Metsera, Inc., and Avalyn Pharma Inc..

2021 was FMR LLC's most active year for acquiring shares with 31 total transactions. FMR LLC's most active month to acquire stocks was the month of September. 2017 was FMR LLC's most active year for disposing of shares, totalling 121 transactions. FMR LLC's most active month to dispose stocks was the month of March. 2023 saw FMR LLC paying a total of $8,767,813.20 for 11,010,670.766 shares, this is the most they've acquired in one year. In 2024 FMR LLC cashed out on 2,039,420 shares for a total of $28,339,746.86, their largest year based on trade value.